Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update
August 15, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell chimerism, and all three patients who were...
Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update
June 30, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
All three FREEDOM-1 patients treated with FCR001 who are more than 12 months post-transplant have been successfully weaned off chronic anti-rejection drugs All FREEDOM-1 patients who received FCR001...
Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022
June 07, 2022 16:01 ET
|
Talaris Therapeutics, Inc.
Real-world, retrospective analysis of Phase 2 patients versus matched controls finds FCR001-treated patients have improved kidney function and fewer cardiometabolic complications than patients on...
Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study
June 01, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., June 01, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics to Present at the Jefferies Healthcare Conference
May 31, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., May 31, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022 16:01 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Changes to Board of Directors
May 17, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces First Quarter Financial Results and Corporate Update
May 12, 2022 16:01 ET
|
Talaris Therapeutics, Inc.
Multiple presentations pending at upcoming American Transplant Congress (ATC), as well as concurrent update on ongoing Phase 3 (FREEDOM-1) clinical trial in living donor kidney transplant (LDKT)...
Talaris Therapeutics Announces Upcoming Presentations at American Transplant Congress
May 02, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
Data to be presented include real-world evidence analysis of health outcomes among Phase 2 patients compared to matched controlsUpdated data on Phase 2 study follow-up, COVID-19 patient outcomes also...
Talaris Therapeutics Presents Data on COVID-19 Outcomes Among Kidney Transplant Patients Treated with FCR001
April 06, 2022 16:01 ET
|
Talaris Therapeutics, Inc.
Low rate of COVID-19 infection observed in vaccinated, durably chimeric patients off immunosuppression No evidence of acute kidney injury or impaired renal function in FCR001-treated patients with...